351 related articles for article (PubMed ID: 18032541)
1. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
Svenson M; Geborek P; Saxne T; Bendtzen K
Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
[TBL] [Abstract][Full Text] [Related]
2. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
4. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
5. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
[TBL] [Abstract][Full Text] [Related]
7. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
[TBL] [Abstract][Full Text] [Related]
8. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication].
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Ugeskr Laeger; 2007 Jan; 169(5):420-3. PubMed ID: 17280636
[TBL] [Abstract][Full Text] [Related]
10. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
11. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
Haraoui B; Cameron L; Ouellet M; White B
J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
[TBL] [Abstract][Full Text] [Related]
12. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.
Wolbink GJ; Vis M; Lems W; Voskuyl AE; de Groot E; Nurmohamed MT; Stapel S; Tak PP; Aarden L; Dijkmans B
Arthritis Rheum; 2006 Mar; 54(3):711-5. PubMed ID: 16508927
[TBL] [Abstract][Full Text] [Related]
13. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G
Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126
[TBL] [Abstract][Full Text] [Related]
14. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
[TBL] [Abstract][Full Text] [Related]
16. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
[TBL] [Abstract][Full Text] [Related]
17. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
[TBL] [Abstract][Full Text] [Related]
19. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.
Rojas JR; Taylor RP; Cunningham MR; Rutkoski TJ; Vennarini J; Jang H; Graham MA; Geboes K; Rousselle SD; Wagner CL
J Pharmacol Exp Ther; 2005 May; 313(2):578-85. PubMed ID: 15647331
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis.
Amital H; Barak V; Winkler RE; Rubinow A
Ann N Y Acad Sci; 2007 Sep; 1110():649-60. PubMed ID: 17911480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
